ELX/TEZ/IVA + IVA
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis
Trial Timeline
Oct 9, 2018 → Jan 9, 2023
NCT ID
NCT03525574About ELX/TEZ/IVA + IVA
ELX/TEZ/IVA + IVA is a phase 3 stage product being developed by Vertex Pharmaceuticals for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03525574. Target conditions include Cystic Fibrosis.
What happened to similar drugs?
20 of 20 similar drugs in Cystic Fibrosis were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04058210 | Pre-clinical | Completed |
| NCT04702360 | Pre-clinical | Completed |
| NCT06460506 | Phase 3 | Active |
| NCT05882357 | Phase 3 | Completed |
| NCT05331183 | Phase 3 | Active |
| NCT05274269 | Phase 3 | Completed |
| NCT05153317 | Phase 3 | Completed |
| NCT05111145 | Phase 3 | Completed |
| NCT04969224 | Phase 3 | Completed |
| NCT04599465 | Phase 3 | Completed |
| NCT04545515 | Phase 3 | Completed |
| NCT04537793 | Phase 3 | Completed |
| NCT04353817 | Phase 3 | Completed |
| NCT04362761 | Phase 3 | Completed |
| NCT04183790 | Phase 3 | Completed |
| NCT04058366 | Phase 3 | Completed |
| NCT04043806 | Phase 3 | Completed |
| NCT03525574 | Phase 3 | Completed |
| NCT03691779 | Phase 3 | Completed |
Competing Products
20 competing products in Cystic Fibrosis